PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Deploys Winning R&D Strategy
Smaller companies achieve higher R&D productivity Collaboration with academia key to R&D success Diverse projects increase chance of success Big Pharma is losing the game in drug development. A decade ago, McKinsey & Company sounded the alarm, warning that the biopharma industry was afflicted by “diminishing R&D productivity.” Despite a doubling of investment in research and development, approvals of “new molecular entities” had fallen precipitously (http://ibn.fm/jUNpt). Nothing appears to have changed since then. A recent report by Deloitte laments the continued decline of returns on R&D investment. While R&D costs have generally remained the same, product revenues are falling, in part…